<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Five Star Senior Living Inc.

    Five Star Senior Living Inc.

    Five Star Senior Living Inc. is a senior living and healthcare services company. A...

    Five Star Senior Living Inc. is a senior living...

    Filing Type:    PU
    NeuBase Therapeutics, Inc.

    NeuBase Therapeutics, Inc.

    NeuBase Therapeutics, Inc. is developing its modular peptide-nucleic acid antisens...

    NeuBase Therapeutics, Inc. is developing its mo...

    Filing Type:    PU
    Moleculin Biotech, Inc.

    Moleculin Biotech, Inc.

    Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the ...

    Moleculin Biotech, Inc. is a clinical stage pha...

    Filing Type:    PU
    ReWalk Robotics Ltd.

    ReWalk Robotics Ltd.

    ReWalk Robotics (Nasdaq: RWLK) is an innovative medical device company. We design,...

    ReWalk Robotics (Nasdaq: RWLK) is an innovative...

    Filing Type:    PU
    Biolase, Inc.

    Biolase, Inc.

    BIOLASE, Inc. is a medical device company and global market leader in the manufact...

    BIOLASE, Inc. is a medical device company and g...

    Filing Type:    PU
    EDAP TMS S.A.

    EDAP TMS S.A.

    Global leader in therapeutic ultrasound and present in the market for more than 35...

    Global leader in therapeutic ultrasound and pre...

    Filing Type:    PU
    Immutep Limited

    Immutep Limited

    We are a biotechnology company developing novel immunotherapy treatments for cance...

    We are a biotechnology company developing novel...

    Filing Type:    PU
    Phio Pharmaceuticals Corp.

    Phio Pharmaceuticals Corp.

    Phio Pharmaceuticals is focused on developing the next generation of immuno-oncolo...

    Phio Pharmaceuticals is focused on developing t...

    Filing Type:    PU
    SELLAS Life Sciences Group, Inc.

    SELLAS Life Sciences Group, Inc.

    SELLAS Life Sciences Group, Inc. is a late-stage biopharmaceutical company focused...

    SELLAS Life Sciences Group, Inc. is a late-stag...

    Filing Type:    PU
    Mustang Bio, Inc.

    Mustang Bio, Inc.

    Mustang Bio, Inc. (“Mustang”), a Fortress Biotech Company, is a clinical-stage...

    Mustang Bio, Inc. (“Mustang”), a Fortress B...

    Filing Type:    PU
    TRACON Pharmaceuticals, Inc.

    TRACON Pharmaceuticals, Inc.

    TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused...

    TRACON Pharmaceuticals, Inc. is a clinical stag...

    Filing Type:    PU
    Adaptimmune Therapeutics PLC

    Adaptimmune Therapeutics PLC

    Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer ...

    Adaptimmune is a leader in TCR T-cell therapy, ...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.